Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists Orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
It can be difficult to decipher which weight loss drug provides better results for patients, as each person reacts differently
Many people find this easier than remembering a daily tablet
N Engl J Med 375:18341844 Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, hman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF (2017) EXSCEL Study Group
A beautiful, balanced plate does not help much if it feels impossible to eat
They offer therapeutic benefits in obesity, cardiovascular health, kidney function, substance use disorders, and even neurodegenerative diseases